Institut Pasteur

Centre National De La Recherche Scientifique

Invectys

Other

Institut Pasteur and Centre National De La Recherche Scientifique

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Simon Wain-Hobson

Pierre Sonigo

Marc Alizon

Luc Montagnier

Oliver Danos

Cole Stewart

Jean-Claude Chermann

Pierre Tiollais

Pierre Langlade Demoyen

Christelle Liard

Stewart T Cole

Solange Chamaret

Francoise Barre Sinoussi

Robert C Gallo

Francoise Barre-Sinoussi

Christine Rouzioux

Mangalasseril G Sarngadharan

Bernard Krust

Mikulas Popovic

Willy Rozenbaum

Francoise Rey

Charles Dauguet

Claudine Axler-Blin

Marie-Therese Nugeyre

Olivier Danos

Thierry Huet

Elodie Pliquet

Francois Brun-Vezinet

Jacques Gruest, Legal Representative

Jean-Pierre Vartanian

Francoise Brun-Vezinet

Fran&ccedil;ois Clavel

Francedillaois Clavel

François Clavel

Luc Montangnier

Fran&ccedil;oise Barre-Sinoussi

Eric Delaporte

Francedillaoise Barre-Sinoussi

Miguel Angel Martinez

Valerie Pezo

Anna Kostrzak

Francoise Barre

Françoise Barre-Sinoussi

The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Telomerase encoding DNA vaccine

The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.

Cancer vaccine for cats

The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Cancer vaccine for dogs

The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

Method of treating fibrosarcoma using a nucleic acid sequence encoding APOBEC3A

A method for enriching a mutant nucleic acid in a mixture of nucleic acids, wherein the method comprises: (a) providing a nucleic acid mixture comprising a parental nucleic acid and a mutant nucleic acid of the parental nucleic acid; and (b) amplifying the nucleic acids in the nucleic acid mixture by polymerase chain reaction (PCR); wherein the mutant nucleic acid is a G&#x2192;A mutant of the parental nucleic acid, which pairs with a fully complementary nucleic acid sequence to form an AT-rich nucleic acid variant of the parental nucleic acid; and wherein the AT-rich nucleic acid variant is denatured and selectively amplified by carrying out PCR using a denaturation temperature 1-3&#xb0; C. lower than the lowest denaturation temperature (T) that allows amplification of the parental nucleic acid to thereby enrich the mutant nucleic acid in the nucleic acid mixture.

Differential amplification of mutant nucleic acids by PCR in a mixture of nucleic acids

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.

Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.

Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV)

The present invention relates to methods and compositions for preventing the occurrence or progression of a cancer or pre-cancerous condition associated with expression, or over-expression of human cytidine deaminases of the APOBEC3 family. The invention also relates to drug screening assays designed to identify compounds that regulate the activity, or level of expression, of hA3A, hA3C and hA3H. The invention further relates to transgenic mice, as well as cells derived from said mice, that have been genetically engineered to express, or over-express hA3A, hA3C and/or hA3H. Such mice may be utilized to screen for, or identify, compounds that modulate the activity, or expression, of the human cytidine deaminases. The present invention also provides topical compositions such as cosmetic lotion, cr&#xe8;me, or sunscreen for use on the skin, which comprise one or more inhibitors of human cytidine deaminase activity. The present invention relates to a double stranded DNA obtained following opening up of its duplex structure, said DNA being edited with cellular protein normally or abnormally expressed in the nucleus of an eukaryotic cell. The mono stranded DNA derived from the said double stranded DNA is a part of the present invention.

APOBEC3 mediated DNA editing

A variant of a LAV virus, designated LAVand capable of causing AIDS. The cDNA and antigens of the LAVvirus can be used for the diagnosis of AIDS and pre-AIDS.

[object Object]

The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.

HIV-1 DNA fragments that hybridize to genomic HIV-1DNA

Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus (HIV). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

Growing community of inventors

Montigny le Bretonneux, France

Simon Wain-Hobson